Galbally, Megan http://orcid.org/0000-0003-3909-1918
Wynter, Karen http://orcid.org/0000-0003-4620-7691
Siskind, Dan http://orcid.org/0000-0002-2072-9216
Correll, Christoph U. http://orcid.org/0000-0002-7254-5646
Northwood, Korinne http://orcid.org/0000-0001-6268-547X
Every-Palmer, Susanna http://orcid.org/0000-0001-6455-9741
Funding for this research was provided by:
Monash University
Article History
Accepted: 7 April 2024
First Online: 7 May 2024
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions. The data utilised were supported with funds from the National Institute of Mental Health under contract NO1 MH90001. Dan Siskind is supported by a National Health and Medical Research Council Emerging Leadership Fellowship (GNT1194635).
: Cristoph U. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Tolmar, Vertex and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax and Quantic. Megan Galbally, Karen Wynter, Dan Siskind, Korinne Northwood and Susanna Every-Palmer have no conflicts of interest that are directly relevant to the content of this article.
: As outlined in the protocol paper for CATIE, a CATIE Ethics Committee, chaired by Paul Appelbaum, reviewed all human subjects ethics considerations [].
: As outlined in the protocol paper, all prospective research participants were screened for decisional capacity []. Those who demonstrated adequate decisional capacity to participate in this research study were allowed to decide whether to enter the study. Those who choose to participate signed a consent form and entered the screening phase.
: Not applicable.
: Data are available from a data repository.
: IBM SPSS Statistics syntax is available from the first author on request.
: MG, DS and SE-P contributed to the study conception and design. Data access was provided by CC and DS. Material preparation and data analysis were performed by KW. The first draft of the manuscript was written by MG and KW and all authors commented on previous versions of the manuscript. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.